NCT04709224View on ClinicalTrials.gov

Pharmacokinetics, Safety, and Tolerability of Lumateperone Long-Acting Injectable in Patients With Schizophrenia

PHASE1CompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

December 30, 2020

Primary Completion Date

May 23, 2022

Study Completion Date

May 23, 2022

Conditions
Schizophrenia
Interventions
DRUG

Lumateperone Long-Acting Injectable

Lumateperone Long-Acting Injectable

Trial Locations (2)

90806

Clinical Site, Long Beach

08053

Clinical Site, Marlton

Sponsors
All Listed Sponsors
lead

Intra-Cellular Therapies, Inc.

INDUSTRY